A Pilot Evaluation of the Safety, Tolerability, Pharmacokinetics, and Effectiveness of Memantine in Pediatric Patients with Attention-Deficit/Hyperactivity Disorder Combined Type
Journal of Child and Adolescent Psychopharmacology2007Vol. 17(1), pp. 19–33
Citations Over TimeTop 10% of 2007 papers
Robert L. Findling, Nora McNamara, Robert J. Stansbrey, Rebecca Maxhimer, Antonia Periclou, Allison Mann, Hamish Graham
Abstract
This pilot study suggests that a memantine dose of 20 mg/day may be a safe and possibly effective treatment for pediatric ADHD. Further investigations of memantine in ADHD appear to be warranted.
Related Papers
- → Memantine and Ketamine Differentially Alter NMDA Receptor Desensitization(2017)93 cited
- → Design, synthesis, and evaluation of polyamine-memantine hybrids as NMDA channel blockers(2017)15 cited
- → Memantine inhibits ethanol-induced NMDA receptor up-regulation in rat hippocampal neurons(2005)48 cited
- → In vivo evidence for functional NMDA receptor blockade by memantine in rat hippocampal neurons(2010)15 cited
- → P1‐247: Efficacy and tolerability of Memantine in Alzheimer's disease ‐ results of an observational study(2009)